期刊文献+

Gefitinib获得性耐药产生时非小细胞肺癌上皮性标志EGFR及E-cadherin表达的变化 被引量:2

Expressions of EGFR and E-cadherin in non-small cell lung cancer with acquired resistance to gefitinib
下载PDF
导出
摘要 [目的]了解gefitinib获得性耐药产生时非小细胞肺癌上皮性标志EGFR及E-cadherin表达的变化。[方法]采用逐步递增药物浓度、间歇作用体外诱导法诱导人肺腺癌NCI-H1975细胞株gefitinib获得性耐药;倒置显微镜下观察亲本细胞株和耐药细胞株在gefitinib作用前后的细胞形态学变化差异;细胞计数法描绘耐药细胞株和亲本细胞株的生长曲线并计算群体倍增时间;免疫细胞化学法检测耐药细胞株及亲本细胞株的EGFR及E-cadherin蛋白表达状态,并比较二株细胞间两种蛋白表达的差异。[结果]历时6个月诱导建成人肺腺癌gefitinib耐药细胞株NCI-H1975/GR。Gefitinib作用后耐药细胞株NCI-H1975/GR的细胞形态变化与亲本株NCI-H1975有所不同;在gefitinib的作用下,NCI-H1975/GR细胞体积变小,部分细胞变为纺锤形;NCI-H1975/GR细胞株群体倍增时间延长7.14 h(P<0.05);免疫细胞化学结果显示:与亲本株比较,虽然耐药细胞株NCI-H1975/GR细胞细胞膜EGFR蛋白的表达无明显变化,但在细胞浆的表达明显增高;E-cadherin在细胞膜的表达明显降低。[结论]非小细胞肺癌产生gefitinib获得性耐药后EGFR蛋白在细胞浆积聚;而以E-cadherin为代表的上皮分化标记表达减弱。 [ Objective] To understand the expression changes of EGFR and E -cadherin as epithelial markers in NSCLC with acquired resistance to gefitinib. [ Methods] The cell line NCI- H1975 was induced to develop gefitinib acquired re- sistance by repeated intermittent exposure to the drug in increasing concentration. The morphological changes between par- ent and drug resistant cell lines before and after gefitinib exposure were observed under inverted microscope. The growth curves of parent and drug resistant cell lines were depicted with eytometry, and population doubling times of parent and drug cell lines were calculated ; The protein expressions of EGFR and E - cadherin were detected by immunocytochemistry and the expression differences of them between parent and drug cell lines were compared. [ Results] The drug resistant cell line NCI - H1975/GR was established for over 6 month. The morphologic change of NCI - H1975/GR cells was different from that of NCI - H1975 cells following exposure to gefitinb. The NCI - H1975/GR cells became smaller and some cells were spindle in shape following exposure to gefitinb. The population doubling time was postponed 7.14 h ( P 〈 0.05 ). The cytoplasm expression of EGFR of NCI - H1975/GR ceils was significantly stronger than that of NCI - H1975, while no dis- tinct difference of the expression in cell membrane between the two cell lines. The membrane expression of E - cadherin in NCI -H1975/GR cells was weaker than that in NCI - H1975. [ Conclusion] There is EGFR cytoplasm accumulation in NSCLC cells following development of acquired resistance to gefitinib in vitro, but the expression of E - cadherin as the epi- thelial differentiated marker decreases in the ceils.
出处 《大连医科大学学报》 CAS 2012年第3期211-215,共5页 Journal of Dalian Medical University
基金 国家自然科学基金项目(81071805)
关键词 非小细胞肺癌 GEFITINIB 获得性耐药 EGFR E—cadherin non - small cell lung cancer gefitinib acquired resistance EGFR E - cadherin
  • 相关文献

参考文献12

  • 1Carlson J J, Garrison LP, Ramsey SD, et al. Epidermal growth factor receptor genomic variation in NSCLC patientsreceiving tyrosine kinase inhibitor therapy: a systematic re- view and meta - analysis [ J ]. J Cancer Res Clin Oncol, 2009,135 ( 11 ) : 1483 - 1493.
  • 2Deng QF, Zhou CC, Su CX. Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial -mesenchymal transition in non- small cell lung cancer [ J . Respirology ,2009,14 (3) :371 - 376.
  • 3Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR muta- tion and resistance of non - small - cell lung cancer to ge- fitinib[ J]. N Engl J Med,2005 ,352 :786 - 792.
  • 4Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associat- ed with a second mutation in the EGFR kinase domain[ J]. PLoS Med,2005,2(3) :e73.
  • 5Bean J, Brennan C, Shih JY, et al. MET amplification oc- curs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [ J J. Prcc Natl Acad Sci USA,2007,104(52) :20932 -20937.
  • 6Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET am- plification leads to gefitinib resistance in lung cancer by ac- tivating ERBB3 signaling [ J ]. Science, 2007,316 ( 5827 ) : 1039 - 1043.
  • 7Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomasto gefitinib or erlotinib[ J. PLoS Med, 2005,2( 1 ) :el7.
  • 8Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitiv- ity and predicts clinical activity of erlotinib in lung cancer patients [ J ]. Chn Cancer Res,2005,11 (24) : 8686 - 8698.
  • 9Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor ) :775 - 787. extracellular domains[ J]. Ce11,2002,110(6.
  • 10I Schlessinger J. Ligand - induced, receptor - mediated dimerization and activation of EGF receptor [ J 1. Cell, 2002,110 (6) : 669 - 672.

同被引文献25

  • 1Thiery Jean Paul. Epithelial - mesenchymal transitions in tumour progression [ J ]. Nature Reviews Cancer, 2002,2 : 442 - 454.
  • 2Sato M, Shames DS, Hasegawa Y. Emerging evidence of epithelial- to- mesenchymal transition in lung carcinogen- esis [ J ]. Respirology, 2012,17 : 1048 - 1059.
  • 3Yasuto Uehikado, Shoji Natsugoe, Hiroshi Okumura, et al. Slug expression in the E - cadherin preserved tumors is re- lated to prognosis in patients with esophageal squamous cell carcinoma[ J]. Cli Cancer Res ,2005,11 : 1174 - 1180.
  • 4Dandachi N, Hauser - Kronberger C, More E, et al. Co - expression of tenascin - c and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumor progression:correlation with histopathological param- eters, hormone receptors, and oncoproteins [ J ]. Pathol 2001,193(2) :181 - 189.
  • 5Liu D, Huang C, Kamceyama K, et al. E - cadherin expres- sion associated with differentiation and prognosis in patients with non - small cell lung cancer [ J ]. Ann Thorac Surg, 2001,71 (3) :949 - 954.
  • 6S A1 - Saad, K A1 - Shibli, Donnem T, et al. The prognostic impact of NF - Kappa B p105, vimentin, E - cadherin and Par6 expression in epithelial and stromal compartment in non- small cell lung cancer [ J ]. Br J Cancer, 2008,99 (9) :1476 - 1483.
  • 7Robert L Yauch, Thomas Januario, David A Eberhard, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients [ J ]. Clin Cancer Res, 2005, 11: 8686 - 8698.
  • 8Miyanaga A, Gemma A, Ando M, et al. E - cadherin espression and epidermal growth factor receptor mutation status predict outcome in non - small cell lung cancer pa- tients treated with gefitinib [ J ]. Oncol Rep, 2008, 19 : 377 - 383.
  • 9Nurwidya F, Takahashi F, Murakami A, et al. Acquired resist- ance of non-small cell lung cancer to epidermal growth factor re- ceptor tyrosine kinase inhibitors [J]. Respir Investig, 2014, 52 (2) :82-91.
  • 10Rho JK, Choi Y J, Lee JK, et al. Epithelial to mesenchymal tran- sition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line[J]. Lung Cancer,2009,63(2) :219-226.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部